🎉 M&A multiples are live!
Check it out!

Transgene Valuation Multiples

Discover revenue and EBITDA valuation multiples for Transgene and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Transgene Overview

About Transgene

Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.


Founded

1979

HQ

France
Employees

167

Website

transgene.fr

Financials

LTM Revenue $18.1M

LTM EBITDA -$24.9M

EV

$73.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Transgene Financials

Transgene has a last 12-month revenue of $18.1M and a last 12-month EBITDA of -$24.9M.

In the most recent fiscal year, Transgene achieved revenue of $0.3M and an EBITDA of -$33.3M.

Transgene expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Transgene valuation multiples based on analyst estimates

Transgene P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.3M $0.3M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$22.1M -$33.3M XXX XXX XXX
EBITDA Margin -1739% -10101% XXX XXX XXX
Net Profit -$35.2M -$24.0M XXX XXX XXX
Net Margin -2771% -7273% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Transgene Stock Performance

As of April 15, 2025, Transgene's stock price is EUR 1 (or $1).

Transgene has current market cap of EUR 84.9M (or $91.2M), and EV of EUR 68.3M (or $73.3M).

See Transgene trading valuation data

Transgene Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$73.3M $91.2M XXX XXX XXX XXX $-0.19

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Transgene Valuation Multiples

As of April 15, 2025, Transgene has market cap of $91.2M and EV of $73.3M.

Transgene's trades at 4.0x LTM EV/Revenue multiple, and -2.9x LTM EBITDA.

Analysts estimate Transgene's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Transgene and 10K+ public comps

Transgene Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $73.3M XXX XXX XXX
EV/Revenue 222.4x XXX XXX XXX
EV/EBITDA -2.2x XXX XXX XXX
P/E -2.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Transgene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Transgene Valuation Multiples

Transgene's NTM/LTM revenue growth is 82%

Transgene's revenue per employee for the last fiscal year averaged $2K, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Transgene's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Transgene's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Transgene and other 10K+ public comps

Transgene Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -74% XXX XXX XXX XXX
EBITDA Margin -10101% XXX XXX XXX XXX
EBITDA Growth 51% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -10018% XXX XXX XXX XXX
Revenue per Employee $2K XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1190% XXX XXX XXX XXX
R&D Expenses to Revenue 11165% XXX XXX XXX XXX
Opex to Revenue 11724% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Transgene Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Transgene M&A and Investment Activity

Transgene acquired  XXX companies to date.

Last acquisition by Transgene was  XXXXXXXX, XXXXX XXXXX XXXXXX . Transgene acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Transgene

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Transgene

When was Transgene founded? Transgene was founded in 1979.
Where is Transgene headquartered? Transgene is headquartered in France.
How many employees does Transgene have? As of today, Transgene has 167 employees.
Who is the CEO of Transgene? Transgene's CEO is Dr. Alessandro Riva, M.D..
Is Transgene publicy listed? Yes, Transgene is a public company listed on PAR.
What is the stock symbol of Transgene? Transgene trades under TNG ticker.
When did Transgene go public? Transgene went public in 1998.
Who are competitors of Transgene? Similar companies to Transgene include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Transgene? Transgene's current market cap is $91.2M
What is the current revenue of Transgene? Transgene's last 12-month revenue is $18.1M.
What is the current EBITDA of Transgene? Transgene's last 12-month EBITDA is -$24.9M.
What is the current EV/Revenue multiple of Transgene? Current revenue multiple of Transgene is 4.0x.
What is the current EV/EBITDA multiple of Transgene? Current EBITDA multiple of Transgene is -2.9x.
What is the current revenue growth of Transgene? Transgene revenue growth between 2023 and 2024 was -74%.
Is Transgene profitable? Yes, Transgene is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.